Novavax, Inc (NASDAQ:NVAX) does about 8.41M shares in volume on a normal day but saw 5082224 shares change hands in the recent trading day. The company now has a market cap of 1.20B USD. Its current market price is $7.41, marking a decrease of -0.54% compared to the previous close of $7.45. The 52 week high reached by this stock is $19.50 whilst the lowest price level in 52 weeks is $5.01. The script in recent trading has seen the stock touch a high of $174 and a low of $14.
16 analysts observing the Novavax, Inc (NVAX) stock have set the 12-month price targets for the company’s shares at between $14 and $174. The consensus objective for the share price is $14.67, suggesting that the stock has a potential upside of 49.49% over the period. The median price target is 66.32% away from the current levels at $22.
FactSet Research has provided data showing that 16 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 10 analysts have rated it as a buy and 6 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 28, 2025 when BTIG Research initiated the stock to “Buy” and issued a price target of $19. JP Morgan downgraded the stock to “Underweight” from Neutral on July 30, 2024 at a price target of $8.
The current price level is 5.30%, 11.98%, and -16.58% away from its SMA20, SMA50, and SMA200 respectively, with the NVAX price moving below the 50-day SMA on current market day. Novavax, Inc (NVAX) stock is up 4.81% over the week and 11.26% over the past month. Its price is -7.84% year-to-date and -64.66% over the past year.
Its 12-month price target is $22. To reach the target analysts have set, the stock logically needs to grow 49.49 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $14, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $174.
Outstanding shares total 161.96M with insiders holding 8.74% of the shares and institutional holders owning 57.28% of the company’s common stock. The company has a return on investment of 324.46%. The price to earnings ratio (P/E ratio) amounts to 2.80 while the forward price to earnings ratio is 20.79. The beta has a value of 2.77. Price to sales ratio is 0.96.
